» Authors » Laure Lacoin

Laure Lacoin

Explore the profile of Laure Lacoin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 128
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kone-Paut I, Georgin-Lavialle S, Belot A, Jover M, Pouriel M, Lacoin L, et al.
Arthritis Res Ther . 2024 Apr; 26(1):80. PMID: 38589954
Background: Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor...
2.
Wolf A, Stratmann J, Shaid S, Niklas N, Calleja A, Ubhi H, et al.
BMC Pulm Med . 2023 Jan; 23(1):16. PMID: 36639770
Background: Immune checkpoint inhibitors (ICIs) have improved outcomes for patients with advanced non-small cell lung cancer (NSCLC) versus chemotherapy in clinical trials. In Germany, ICIs have been used clinically since...
3.
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, et al.
Cancers (Basel) . 2022 Dec; 14(24). PMID: 36551632
This study reports characteristics and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) receiving nivolumab in second-line or later (2L+) in France and Germany between...
4.
Griesinger F, Perol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, et al.
Lung Cancer . 2022 Aug; 172:65-74. PMID: 36007281
Objectives: To describe the impact of immune checkpoint inhibitors (ICIs) on treatment patterns and survival outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) in France...
5.
Carroll R, Bortolini M, Calleja A, Munro R, Kong S, Daumont M, et al.
BMC Cancer . 2022 Mar; 22(1):255. PMID: 35264135
Background: As part of the multi-country I-O Optimise research initiative, this population-based study evaluated real-world treatment patterns and overall survival (OS) in patients treated for advanced non-small cell lung cancer...
6.
Baas P, Daumont M, Lacoin L, Penrod J, Carroll R, Venkatesan S, et al.
Lung Cancer . 2021 Nov; 162:185-193. PMID: 34823894
Objectives: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with a poor prognosis and limited treatment options. This study assessed the characteristics, treatment patterns, and outcomes for patients...
7.
Sorensen J, Horvat P, Rosenlund M, Kejs A, Patel D, Juarez-Garcia A, et al.
Future Oncol . 2021 Nov; 18(2):205-214. PMID: 34784783
To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Adults diagnosed with...
8.
Ekman S, Horvat P, Rosenlund M, Kejs A, Patel D, Juarez-Garcia A, et al.
JTO Clin Res Rep . 2021 Sep; 2(5):100165. PMID: 34590017
Introduction: SCAN-LEAF, part of the I-O Optimise initiative, is a retrospective, longitudinal study investigating the epidemiology, clinical care, and outcomes for patients with NSCLC in Scandinavia. We report overall survival...
9.
Snee M, Cheeseman S, Thompson M, Riaz M, Sopwith W, Lacoin L, et al.
BMJ Open . 2021 Sep; 11(9):e046396. PMID: 34526333
Objectives: To report characteristics, treatment and overall survival (OS) trends, by stage and pathology, of patients diagnosed with non-small cell lung cancer (NSCLC) at Leeds Teaching Hospital NHS Trust in...
10.
Soares M, Antunes L, Redondo P, Borges M, Grimson F, Hermans R, et al.
Eur J Cancer Care (Engl) . 2021 Jul; 30(6):e13496. PMID: 34288191
Objective: We aim to describe treatment patterns and overall survival (OS) among a Portuguese cohort of patients with small cell lung cancer (SCLC). Methods: This study utilised a database held...